

# A randomized prospective study investigating the optimum power settings for selective laser trabeculoplasty (SLT) in ocular hypertension (OHT) and primary open angle glaucoma (POAG)

<b>Submission date</b> 28/09/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 28/09/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 07/12/2010	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Mr Avinash A Kulkarni

### Contact details

Lambeth Road  
London  
United Kingdom  
SE1 7EH  
+44 (0)2071887188

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0013184505

# Study information

## Scientific Title

### Study objectives

At the present time, although SLT is accepted as a viable treatment for OHT / POAG, there has not been a thorough assessment of the optimum Laser power settings which enable safe and effective treatment. This study aims to scientifically compare high power settings with low power settings, investigating the efficacy of treatment in lowering intraocular pressure during the follow-up period after treatment, and the incidence of adverse events related to Laser treatment. Secondary Research Objectives: None

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Eye Diseases: Ocular hypertension (OHT)

### Interventions

Research participants are to be recruited from the NHS glaucoma clinic at St. Thomas' Hospital over a 6 months period, starting 1st May 2004. Eligible participants will be patients with OHT or POAG, which is uncontrolled in one or both eyes despite maximal topical medical therapy. We aim to recruit 60 patients.

Each patient will be randomized to treatment with the Laserex Solo SLT Glaucoma Laser in one of three treatment groups:

Group 1 will receive high-energy SLT (1.2mJ shots) in one or both eyes

Group 2 will receive medium energy SLT (0.8mJ shots) in one or both eyes

Group 3 will receive low-energy SLT (0.4mJ shots) in one or both eyes.

The decision to treat either one or both eyes will depend on whether the intraocular pressure is too high in one or both eyes. Therefore only eyes with uncontrolled pressure will be treated. Some patients may have both eyes treated. In these cases data for the study will only be collected for one eye. Thus, in total, 20 patients will be allocated to each of the 3 groups with 20 eyes per group (one per patient).

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

1. Visual field defect progression
2. Disc cup appearances

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/08/2005

**Completion date**

01/08/2006

**Eligibility****Key inclusion criteria**

Patients with OHT or POAG, which is uncontrolled despite maximal topical medical therapy.

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Not Specified

**Target number of participants**

40

**Key exclusion criteria**

Patients who do not meet inclusion criteria

**Date of first enrolment**

01/08/2005

**Date of final enrolment**

01/08/2006

## **Locations**

### **Countries of recruitment**

England

United Kingdom

### **Study participating centre**

**Lambeth Road**

London

United Kingdom

SE1 7EH

## **Sponsor information**

### **Organisation**

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

### **Sponsor details**

The Department of Health

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

+44 (0)20 7307 2622

dhmail@doh.gsi.org.uk

### **Sponsor type**

Government

### **Website**

<http://www.dh.gov.uk/Home/fs/en>

## **Funder(s)**

### **Funder type**

Government

### **Funder Name**

**Funder Name**

Own account

**Funder Name**

NHS R&D Support Funding

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/11/2010		Yes	No